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Mutations in the androgen receptor gene in 46,XY individuals can be associated with the androgen 
insensitivity syndrome, of which the phenotype can vary from a female phenotype to an undervirilized 
or infertile male phenotype. We have studied the androgen receptor gene of androgen insensitivity 
patients to get information about amino acid residues or regions involved in DNA binding and 
transcription activation. Genomic DNA was analysed by PCR-SSCP under two different conditions. 
Three new mutations were found in exon 1 of three patients with a female phenotype. A cytosine 
insertion at codon 42 resulted in a frameshift and consequently in the introduction o f a premature stop 
at codon 171. Deletion of an adenine at codon 263 gave rise to a premature stop at codon 292. In both 
these cases, receptor protein was not detectable and hormone binding was not measurable. In a third 
patient, a guanine-to-adenine transition at codon 493 converted a tryptophan codon into a stop codon. 
Genital skin fibroblasts from this patient were not available. In exon 2 of the androgen receptor gene 
of a patient with receptor-positive androgen insensitivity, a cytosine-to-adenine transition, converting 
alanine 564 into an aspartic acid residue, resulted in defective DNA binding and transactivation. In 
three other receptor-positive androgen insensitivity patients no mutations were found with 
PCR-SSCP. Copyright © 1996 Elsevier Science Ltd.
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INTRODUCTION
Androgens play a major role in male sexual differen­
tiation and development. The actions of androgens are 
exerted through the androgen receptor (AR) which 
modulates transcription of androgen-responsive genes. 
The AR belongs to a super-family of receptors for 
steroid hormones, thyroid hormones and retinoids. 
Characteristic for the members of this family are the 
distinct functional domains; the N-terminal domain 
involved in transcription regulation, a D NA  binding 
domain, composed of two zinc fingers, a hinge region 
and the C terminal ligand binding domain [1 ]. 
Mutations in the AR in 46,XY individuals are 
associated with the androgen insensitivity syndrome 
(AIS), a disorder with a wide spectrum of phenotypes.
* Correspondence to H. T. Brüggenwirth.
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Subjects with complete AIS exhibit a female phenotype, 
whereas other AIS subjects show a phenotype with 
ambiguous genitalia, called partial AIS. The majority of 
the mutations reported up to now are point mutations, 
located in the ligand binding domain [2 , 3]. AIS 
subjects with an AR of normal molecular mass and no 
abnormalities in ligand binding are an interesting 
group, because they may provide information about 
essential amino acid residues or regions, directly 
involved in transcription activation, Deletion mapping 
revealed that almost the entire N-terminal domain is 
necessary for full AR receptor transactivating activity 
[4]. Therefore, AR mutations interfering with correct 
receptor functioning may be expected in this domain. 
However, except for the expanded glutamine stretch, 
associated with Kennedy’s disease, only six mutations 
in exon 1 of the ARhave been reported [5-10]. Five of 
these resulted either directly or indirectly in the 
introduction of a premature stop codon.
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In this study we describe three new exon 1 mutations, 
all resulting in the introduction of premature stop 
codons. Zoppi et a l  [10] reported a patient in which a 
single nucleotide substitution resulted in a premature 
stop at codon 60. Synthesis of AR protein was found 
to be initiated downstream of the termination codon. 
Therefore, we have investigated whether truncated AR 
forms were present in genital skin fibroblasts of the 
patients with an exon 1 mutation. A new mutation was 
also detected in the first zinc finger of the DNA binding 
domain of a patient with receptor-positive AIS. No  
exon 1 mutations, resulting in receptor-positive AIS, 
were found. In three other patients with receptor- 
positive AIS3 no mutation was detected by polymerase 
chain reaction-single-strand conformation polymorphism
(PCR-SSCP) analysis.
MATERIALS AND M ETHODS
Clinical subjects
Subject A: 46,XY index patient with complete AIS 
was admitted at the age of 1 yr because of a bilaterally 
inguinal hernia. She has a younger 46,XY sister with the 
same phenotype.
Subject B: 46,XY patient, diagnosed as having 
complete AIS. The sister of the patient’s mother was 
known with primary amenorrhea.
Subject C: 46,XY patient, with a complete female 
phenotype and from a family with more affected 
members.
Subject D: 46,XY patient who was diagnosed as 
having complete AIS at birth in the absence of a positive 
family history. She came to medical attention because 
of suspected dysmorphology. After further clinical 
examination the diagnosis of AIS was made.
Subjects without a mutation: All patients displayed a 
46,XY chromosome pattern, had no mullerian duct 
remnants and male hormonal levels were present in the 
serum. Two of them have the typical phenotype of 
complete AIS and one case has a phenotype with 
ambiguous genitalia.
The phenotype and the AR gene mutation of each 
subject are summarized in Table 1.
Table L Summary of phenotypes and AR gene mutations of index
subjects
Subject Phenotype Mutation Position change
A cAlS C insertion codon 42
B cAIS A deletion codon 263
C cAIS TGG-^TGA Trp493Stop
D cAIS GCT-+GAT Ala564Asp
E pAIS no mutation*
F cAIS no mutation'*
G cAIS no mutation*
The amino acid numbering is based on 910 residues, corresponding 
to a glutamine stretch of 20 residues and a glycine stretch of 16 
residues.
*Only screened by PCR-SSCP.
M utation detection
Genomic DNA, isolated from blood lymphocytes, 
was screened by PCR-SSCP. Seventeen primer sets for 
overlapping fragments were used to amplify the coding 
region and the exon flanking intronic regions of the 
hAR. A 15 pi PCR reaction mixture was used, 
containing 100 ng genomic DNA, 70 ng of each 
oligonucleotide, 40 jaM of each dNTP, 10  mM Tris 
HCl (p H  9.0), 1.5 mM MgCl2, 5 mM KC1, 10% 
DMSO (in case of amplifying exon 1), 1 .0  jj.Ci [a 32P] 
dATP (Amersham, Little Chalfont, Bucks., U.K.) and 
0.1 unit Supertaq DNA polymerase (HT Biotechnology 
Ltd, Sphaero Q, Leiden, The Netherlands). For PCR 
fragments covering the glycine stretch, 50% deaza 
dGTP was used with 50% dGTP. Reactions were 
denatured at 95°C and subjected to 30 cycles of 
dénaturation at 95°C for 1 min, annealing for 2 min at 
different temperatures (Table 2) and elongation at 
72°C for 1 min. In Table 2 oligonucleotides used for 
PCR amplification of the human AR gene and for direct 
sequencing are indicated. Samples consisting of 1 jil of 
PCR product and 9 |J sample buffer (95% formamide, 
5% glycerol, 20 mM EDTA, 0.02% bromophenoi blue 
and 0.02% xylene cyanol FF) were denatured before 
loading onto a gel containing 7% acrylamide, 1 X TBE 
buffer (Tris-borate, pH 8 .2 , 2.5 mM EDTA) and 5% 
or 10% glycerol. Gels were run for 16 h at 6 W either 
with 0.5 x TBE buffer (5% glycerol gels) or l x  TBE 
( 1 0 % glycerol gels) at room temperature. Direct 
sequencing was performed in case an aberrant SSCP 
pattern was detected. Amplification took place in 100 jil 
reaction mixtures containing 100  ng genomic DNA, 
400 ng of each primer, 200 |iM of each dNTP, 10 mM 
Tris-HCl, 1.5 mM MgCl2, 5 mM KC1, 10% DMSO
(in case of amplifying exon one) and 2.5 units Amplitaq 
DNA polymerase (Perkin Elmer, Nieuwenkerk, a/d 
Yssel, The Netherlands). PCR products were purified 
from Seakem agarose with Spin-X columns (Costar, 
Badhoevedorp, The Netherlands) and about 100 ng 
PCR product was used as template in the cycle 
sequencing reaction (Sequitherm kit; Epicenter, 
Biozym, Landgraaf, The Netherlands). Primers, devel­
oped for PCR-SSCP, were end-labelled with T4 
polynucleotide kinase in the presence of [y ” P] dATP 
(Amersham) and used in the cycle sequencing reaction.
Cell culture conditions
Genital skin fibroblasts were cultured in Modified 
Eagle’s medium (MEM, containing 1 0 % fetal calf 
serum, minimal essential amino acids (Gibco, Life 
Technologies, Breda, The Netherlands) and antibiotics 
at 37°C and 5% C 0 2. Fibroblasts were grown to 
confluency, washed two times with PBS-buffer and 
cytosols or whole cell lysates were prepared.
Preparation of whole cell lysates
Genital skin fibroblasts were grown to confluency and 
scraped in 1 ml lysis-buffer (40 mM Tris, 1 mM EDTA
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Table  2. Sequence o f  oligonucleotides used fo r  P C R - S S C P  screening o f  the h u m a n  A R  gene
Oligo Location PCR fragment Annealing temperature (°C) Sequence
-7 0 A 5-U T R j exon 1 Exon 1 A* 55 GCCTG TTG AACTCTTCTG AG C
95B Exon 1 CTTGGGGAGAACCATCCTCA
35A Exon 1 Exon 1 B 58 T c CGCGAAGTGATC C AGAAC
95B Exon 1 CTTGGGGAGAACCATCCTCA
80A Exon 1 Exon 1 C 64 AGCAAGAGACTAGCCCCAGGCAGC
172B Exon 1 C G G  AGC AGCTGCTTAAGC CGGGG
160A Exon 1 Exon 1 D 62 GCTG CCCCATCCACG TTG TCCCTG CT
250B Exon 1 ACTCAGATGCTCCAACGCCTCCAC
240A Exon 1 Exon 1 E 62 TGTGTAAGGCAGTGTCGGTGTCCAT
320B Exon 1 CGCCTTCTAGaCCTTTGGTGTAAC
305A Exon 1 Exon 1 F 64 CAGGCAAGAGCACTGAAGATACTGC
385B Exon 1 GGTTCTCCAGCTTGATGCGAGCGTG
361A Exon 1 Exon 1 G 58 CGCGACTACTACAACTTTCCACTGG
445B Exon 1 CACACGGTCCATACAACTG
1A Exon 1 Exon 1 H 55 T  C CT GG C AC ACT C T  CTTC AC
490B Exon 1 GCCAGGGTACCACACATCAGGT
47 0A Exon 1 Exon 1 I 57 GTAGCCCCCTACGGCTACA
IB Intron 1 CAGAACACAGAGTGACTCTGC
2A Intron 1 Exon 2 55 G TCATTTATG CCTG CAG G TT
2B Intron 2 TCTCTCTCTGGAAGGTAAAG
3A Intron 2 Exon 3 55 T  C A G G T CTAT C A A C T CTTG
3B Intron 3 G G AG AGAGG AAG G AGG AG G A
4A Intron 3 Exon 4 A 55 A T T  C A A G TC T C T C TT  C CTTC
14NB Exon 4 TGCAAAGGAGTtGGGCTGGTTG
4AA Exon 4 Exon 4 B 55 CAGAAGCTtACAGTGTCACACA
4B Intron 4 GCGTTCACTAAATATGATCC
5A Intron 4 Exon 5 55 GACTCAGACTTAGCTCAACC
5B Intron 5 ATGACCACCAACCAGGTCTG
6A Intron 5 Exon 6 55 CAATCAGAGACATTCCTCTGG
6B Intron 6 AG TG G TCCTCTCTG AATCTC
7A Intron 6 Exon 7 55 TG C TC C TTC G TG G G C A TG C T
7B Intron 7 TG G CTCTATCAG G CTG TTCTC
8LA Intron 7 Exon 8 55 AGGC C AC CTC C T T G T C  AAC
8B 3' UTR, exon 8 AAGGCACTGCAGAGGAGTA
‘'This PCR product is relatively large and was therefore digested with the restriction enzyme Pstl3 prior to PCR-SSCP analysis. The 
CAG(n)CAA repeat length was studied with primer pair 35A and 95B. Mismatches are indicated with a small letter.
pH 7.45 10% glycerol, 10 mM dithiothreitol (D T T ), 
1% v/v Triton, 0.08% sodium dodecylsulfate (SDS), 
0.5% sodium-deoxycholate, 600 |iM phenylmethyl- 
sulfonyl fluoride, 500 jiM bacitracin). After 5 min the 
cell extract was centrifuged for 10 min at 4000 RPM at 
5°C. The supernatant was stored at -80°C .
Preparation of cytosols
Cells were scraped in 1 ml cytosol-buffer (40 mM  
Tris, 1 mM EDTA pH 7.4, 1 0 % glycerol, 10 mM  
D T T , 10 mM molybdate, and freshly added: 600 fiM 
phenylmethylsulfonyl fluoride, 500 |tM bacitracin and 
500 mM leupeptin), and homogenized with a teflon 
potter. The derived cell homogenates were centrifuged 
for 10  min at 100,000  x ^ , and the supernatants stored 
at -8 0 °C  until use.
Characterization of the A R  protein by S D S -P A G E  and  
immuno staining
The AR protein was immunoprecipitated from 
genital skin fibroblast lysates, with monoclonal antibody 
F 39.4 .1., as described before [11]. After electrophoresis 
on a 7% sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel, the proteins were 
transferred to nitrocellulose and immunostained with 
polyclonal antibody, Sp061. After washing, the 
membrane was incubated with a second, peroxidase 
coupled antibody, to visualize the protein.
S ca tch ard  analysis
For studying the binding characteristics two different 
assays were used: either a binding assay in which genital 
skin fibroblast cytosols were used, or a whole cell assay. 
Cytosols were incubated overnight at 4°C with 
increasing concentrations (0 -0 .1 -0 .23 -0 .5 -1 .0 -2 .5 -  
5.0—10.0 nM) of 17ß-hydroxy 17a-methyl-3H (3H- 
R1881) (Dupont, Dordrecht, The Netherlands), in the 
absence or presence of a 10 0 -fold molar excess of 
non-labelled R1881 to determine non-specific binding. 
After protamine precipitation to remove the free 
steroid, specifically bound 3H-R1881 was measured. 
The total amount of protein was assayed according to 
the method of Bradford [1 2 ].
Genital skin fibroblasts were incubated with increas­
ing concentrations of 3H-R1881 (0 .02 , 0.05, 0.3, 1.0, 
3.0 nM) to obtain a saturation state. The non-specific
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binding was determined after incubation with a 
100-fold molar excess of non-radio active steroid. After 
a 1 -h incubation period at 37°C, cells were washed four 
times with ice-cold 20 nM Tris, 0,15 mM NaCl, 
pH 7.4. The cells were scraped in 1 ml lysis-buffer
(TEG pH 7.4: 20 mM Tris* 15 mM EDTA, 10% v/v
glycerol, 600 jxM phenylmethylsulfonyl fluoride and 
500 jiM bacitracine). After 10  min centrifugation at 
800 x g  the pellet was lysed by adding 1 ml 0,5 N  
NaOH and a 30 min incubation at 56°C. Scintillation 
cocktail (5 ml Clumin (Packard, Tilburg, The Nether­
lands)) was added to 500 j.il of each sample and 
3H-activity was measured in a scintillation counter. 
The amount of protein was quantified by the method 
of Bradford [12]. Scatchard analysis was carried out 
to determine the dissociation constant (Kd) and the 
number of binding sites (B,uax).
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Fig. 2. Localization of mutations and internal AUGs in exon 1 
of the androgen receptor gene. The mutations found in exon 1 
of the AR gene are shown; + C: insertion o f a cytosine at codon 
42, resulting in a premature stop at codon 171; -A : deletion of 
an adenine at codon 263, resulting in a premature stop at codon 
292. At codon 493 a transition of a guanine to an adenine was 
found, directly resulting in a premature stop codon. 
Translation start sites and the molecular mass o f proteins, 
resulting from translation initiation, governed by these AUGs,
are depicted.
RESULTS
The coding part of the hAR gene was screened by 
amplification of genomic DNA with a set of 18 primer 
pairs, followed by SSCP analysis, performed under two 
different conditions. In case of an aberrant PCR-SSCP
profile, direct sequencing was performed. Three new frameshift and consequently in a premature stop at 
exon 1 mutations, all resulting in the introduction of a codon 171 (Fig. 2). In a second complete AIS subject 
premature stop codon were detected in the hAR of three (B) a deletion of an adenine at codon 263 of the AR  
complete AIS patients (Fig. 1). In one receptor-positive gene gave rise to a stop codon at position 292 (Fig. 2 ),
patient a mutation was found in exon 2 (Fig. 1 ). In 
three other patients, diagnosed as also having a 
receptor-positive form of AIS, no aberrant PCR-SSCP 
pattern was detected.
Sequence analysis indicated a cytosine insertion at 
codon 42 of the AR gene of patient A, resulting in a
E xon  1 E xon  1 E xon 1 E xon 2
A D G
A guanine-to-adenine transition at codon 493 changed 
a tryptophan codon (TGG) into a stop codon (TGA) 
in the AR gene of patient C (Fig. 2). A Kpn I restriction 
site, which is a unique site in AR cDNA, was destroyed 
by the mutation and is informative with respect to 
carrier detection.
We stern-immun ob lotting was performed to investi­
gate if a truncated AR form was expressed in genital 
skin fibroblasts of subjects A and B. Truncated forms 
might result from internal reinitiation of translation,
□ □ □ □
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Fig. 1. PCR-SSCP analysis of androgen receptor gene 
mutations, SSCP analysis o f different parts of exon 1 and of 
exon 2. Lane 1: wild-type AR pattern of fragment A 
[nucleotides ( -7 0 ) - (  + 286)]; lanes 2 and 3: patterns of 
fragment A of index patient A [2] and her 46,XY sister [3]; lane 
4: wild-type pattern o f fragment D (nucleotides 707-958); lane 
5: pattern of fragment D o f patient B; lane 6: wild-type pattern 
of fragment G, starting at nucleotide 1402 and ending in intron 
1; lane 7: SSCP pattern o f fragment G o f patient C; lane 8: 
wild-type pattern o f exon 2 fragment starts in intron 1 and ends 
in intron 2; lane 9: exon 2 pattern o f patient D. Numbers are 
based upon an open reading frame of 2730 nucleotides [13].
kDa ARO + 1 C  -1 A
205
J ' '
. . . .  .
116.5 :• j J- j
*• ' • •
1 2 3
Fig. 3. Western blot analysis of androgen receptor expression. 
AR protein was immunoprecipitated with monoclonal anti­
body F39.4.1 from genital skin fibroblast lysates, and separated  
on a 7% SDS-PAGE gel. After electrophoresis the proteins 
were transferred to nitrocellulose and immunostained with the 
polyclonal antibody SP061. The AR protein was visualized with 
a peroxidase-coupled go at-anti-rabbit antibody. Lane 1: 
Wild-type (Wt) AR from control genital skin fibroblasts (GSF); 
lane 2: AR with insertion of cytosine (+1C ) from GSF of 
subject A; lane 3: AR with deletion o f adenine ( -  1A) from GSF 
of subject B. Molecular mass markers are indicated on the left.
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mutations in the AR gene. Studying new mutations in 
receptor-positive AIS patients may reveal new infor­
mation on amino acid residues in functional domains 
involved in D N A  binding and transcription regulation. 
Besides mutations in exons 2 and 33 encoding the D N A  
binding domain of the AR, exon 1  mutations may be 
expected, because the N-terminal region plays a role in 
transcription activation [4]. In exon 1 of the AR gene 
of three complete AIS patients we have found 
mutations resulting either directly or indirectly in the 
introduction of premature stop codons. Translation 
reinitiation is known to occur in mammalian cell
Fig. 4. Position of the Ala -*Asp mutation in the first zinc 
finger of the androgen receptor DNA binding domain, The 
amino acid sequence of the DNA binding domain o f the AR, 
consisting of two zinc fingers, is shown in  one letter code. The 
first zinc finger contains the P-box in which the three circled 
amino acid residues determine hormone-responsive element 
specificity. Boxes indicate residues that make contacts with the 
phosphate backbone of the DNA, either at specific sites (black 
boxes) or at non-specific sites (open boxes) [14]. The mutation  
is depicted at position 564. In the second zinc finger the D-box  
and part of the nuclear localization signal (NLS) are located.
mRNAs. Mammalian ribosomes can reinitiate trans­
lation at an A UG  codon, after termination at an 
upstream site [15* 16]. According to Peabody et al. [16] 
it may be possible that the 40 S ribosomal subunit 
remains associated with the mRNA, and regains the 
capacity to scan along the mRNA until it encounters an 
initiation codon. At this point, the loose ribosomal 
subunit becomes associated and synthesis o f the 
polypeptide chain starts again. In the Tfm mouse a 
single nucleotide in a hexacytidine stretch (nucleotides 
1107-1112) is deleted in the AR gene, resulting in a 
proceeding from internal AUG codons (Fig. 2 ). In case frame shift and the introduction o f a premature stop at 
of patient A no AR protein of 87 kDa could be detected codon 412. Downstream of this premature stop codon 
(Fig. 3, lane 2). This corresponds with the observation three AUGs are located, in frame with the premature 
that ligand binding was not measurable in cytosols, termination codon, A low level of high affinity binding 
prepared from genital skin fibroblasts of patient A. The to androgens and also to D N A  could still be measured, 
stop codon, introduced in the AR of patient B is also which indicates reinitiation of translation [17-19]. The 
located upstream of an internal in frame AUG. low protein level resulted from instability o f the mRNA  
However, a shortened AR protein could not be detected [17, 18]. Zoppi et a l  [10] described an AIS patient 
on a Western blot (Fig. 3, lane 3). Furthermore ligand in which a cytosine-to-thymine transition, converting 
binding studies were negative. Genital skin fibroblasts a glutamine (CAG) residue at position 60 in the
were not available from patient C.
A new mutation was found in exon 2, which encodes 
the first zinc finger of the DNA binding domain of the
polymorphic glutamine stretch, into a premature stop 
(TAG). In  vitro experiments suggested that internal 
initiation occurs from the first in-frame AUG  codon at
AR. A transition of cytosine to adenine converts an position 188, resulting in a 87 kDa protein. In genital 
alanine residue at position 564 into an aspartic acid skin fibroblasts, a low but detectable level of specific 
residue (position depicted in Fig. 4). This mutation androgen binding with an accelerated dissociation rate
resulted in defective DNA binding and transactivation, 
and will be described in more detail elsewhere.
was measured. In patient A, the premature stop codon 
was present at codon 171. A shortened protein of
In two of the patients, diagnosed as having complete approximately 87 kDa, however, could not be detected 
AIS, and in one patient with partial AIS, no mutation in genital skin fibroblasts. These results correspond 
was found after screening all the exons and their with the observation that binding was not measurable 
flanking intronic sequences with PCR-SSCP. All three in cytosol from the patient’s genital skin fibroblasts. In 
patients were clinically well diagnosed. AR protein was 
isolated from genital skin fibroblasts, obtained from 
these subjects, and molecular mass was established after 
SDS-PAGE and Western blotting. In all cases the AR 
protein migrated as a normal 110-112 kDa doublet.
Receptor characteristics were further studied by Scatch- 
ard analysis, from which it became clear that the AR of the efficiency of reinitiation may be governed by the 
these three patients displayed normal K d and B max values, position of the termination codon^ relative to the
subsequent downstream AUG codons [15, 16, 20 ].
DISCUSSION Pat*erit the new start is located 10 codons
downstream of the premature stop codon, whereas in
Genomic DNA from patients with either complete or the patiènt described by Zoppi et al. [10] and in the Tfm  
partial AIS were screened by PCR-SSCP analysis for mouse, this distance was 128 and 132—134 codons,
the other two mutant AR genes we described, the stop 
codon occurred after the first internal AUG. N o  
truncated receptor proteins could be detected in genital 
skin fibroblasts derived from patient B. It is unclear 
which factors dictate the efficiency with which 
such translation reinitiation occurs. To some extent
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respectively. This may be the reason why, in genital skin 
fibroblasts from this patient A, no 87 kDa AR and 
ligand binding were detected.
Two isoforms of the progesterone receptor (PR) have 
been described, a protein of normal structure (PR-B) 
and a shortened form (PR-A), lacking 164 amino acids 
at the N-terminus [21]. Depending on cell type and 
promoter context, functional differences between the 
two forms have been found. PR-A can act as an 
activator of transcription and as a repressor of 
transcription by PR-B and even as an inhibitor of 
transcription, mediated by the glucocorticoid receptor, 
the mineralocorticoid receptor and the AR [22]. Wilson 
et a l [23] reported that two forms of human AR* 
comparable to PR isoforms, are present in human 
genital skin fibroblasts. A 87 kDa isoform was 
postulated, which constitutes 7-15% of the total AR, 
arising from alternative initiation of translation. We 
were, however, unable to detect such a 87 kDa protein 
in genital skin fibroblasts of a control subject.
Up to now, amino acid substitutions in exon 1 , 
resulting in a receptor-positive form of AIS have not 
been found. However, recently a proline-to-leucine 
substitution at position 339 was found, in DNA isolated 
from a prostate tumour [24]. No functional studies have 
been performed as yet to study the significance of this 
mutation.
The cytosine-to-adenine transition at codon 564, 
converting an alanine residue into an aspartic acid 
residue in the first zinc finger of the DNA binding 
domain of the AR, resulted in a complete AIS 
phenotype. The phenotype was caused by the defective 
DNA binding and transactivation capacities of the 
mutant receptor. Although the correct 3-D structure of 
this mutant AR is not available, the effect of the 
mutation can be deduced from the 3-D structure of the 
glucocorticoid D NA  binding domain [14]. Cysteine 
560, histidine 561, and tyrosine 562 are involved either 
in specific or aspecific contacts with the phosphate 
backbone of the DNA (Fig. 4). The amino acid 
substitution in the mutant receptor might interfere 
with these contacts, resulting in defective DNA  
binding.
In the AR gene of three subjects with an AIS-like 
phenotype, no mutations were found with PCR-SSCP. 
Although receptor characteristics appear to be normal, 
the presence of a mutation, not influencing ligand 
binding, cannot be excluded. There is still a possibility 
that some mutations are being missed by the screening 
procedure we used. However, in our laboratory so far 
all mutations which were previously found by direct 
sequencing, could be confirmed by PCR-SSCP  
afterwards. AR proteins appeared as normal 1 1 0 -  
112 kDa doublets in genital skin fibroblasts and 
furthermore normal K d and B max values were measured. 
This does not rule out abnormal protein expression in 
other target tissues. Another explanation for the 
androgen resistance syndrome might be the presence of
a mutation in a gene, encoding a factor specifically 
involved in transcriptional regulation of AR target 
genes.
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